Expression of E‐ and N‐cadherin and clinicopathology in hepatocellular carcinoma

Pathology International - Tập 58 Số 10 - Trang 635-642 - 2008
Sung Bum Cho1, Kyung Hwa Lee, Jae Hyek Lee, Sun Young Park, Wan‐Sik Lee, Chang‐Hwan Park, Hyun Soo Kim, Sung Kyu Choi, Jong‐Sun Rew
1Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea

Tóm tắt

Loss or reduced E‐cadherin expression and aberrant expression of N‐cadherin have been associated with invasiveness of human carcinoma cells and poor prognosis. The role of E‐ and N‐cadherin, however, in hepatocellular carcinoma (HCC) has not yet been elucidated. The aim of the present study was to investigate the expression pattern of E‐ and N‐cadherin in surgically resected HCC specimens according to their relationship with clinicopathological features. The expression patterns of E‐ and N‐cadherin were evaluated on immunohistochemistry in 68 specimens of HCC and adjacent non‐tumor tissue. The most different expression pattern between HCC and non‐tumor tissue was the decreased staining intensity of E‐cadherin (n = 37, 54%) and the dot‐like discontinuous staining of N‐cadherin (n = 35, 55%). Decreased intensity of E‐cadherin and discontinuous staining of N‐cadherin in HCC was correlated with advanced stage. The risk factors for expression patterns related to recurrence were loss of E‐cadherin expression (odds ratio (OR) = 3.6; 95% confidence interval (CI): 1.1–12.4) and discontinuous staining of N‐cadherin (OR = 1.6; 95% CI: 0.8–3.2). In conclusion, discontinuous staining of N‐cadherin and loss of E‐cadherin expression in HCC predicts a high risk of recurrence after surgical treatment.

Từ khóa


Tài liệu tham khảo

Park JW, 2005, Epidemiology of hepatocellular carcinoma in Korea, Korean J Hepatol, 11, 303

10.1002/hep.1840120411

10.1002/hep.1840160122

10.1097/01.sla.0000201480.65519.b8

10.1002/jso.20389

10.1016/j.ceb.2005.08.014

10.3748/wjg.v11.i20.3139

Ross JS, 1994, E‐cadherin expression in prostatic carcinoma biopsies: Correlation with tumor grade, DNA content, pathologic stage and clinical outcome, Mod Pathol, 7, 835

10.1158/1078-0432.CCR-0578-03

Katoh M, 2005, Epithelial‐mesenchymal transition in gastric cancer, Int J Oncol, 27, 1677

10.1083/jcb.148.4.779

10.1083/jcb.147.3.631

Liver Cancer Study Group of Japan. Primary liver cancer in Japan, 1990, Clinicopathologic features and results of surgical treatment, Ann Surg, 211, 277

Matsumura T, 2001, Frequent down‐regulation of E‐cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas, Clin Cancer Res, 7, 594

10.1038/sj.bjc.6690431

10.1002/hep.1840180402

10.1053/jhep.2002.35342

10.1002/hep.510230621

Huang GT, 1999, Correlation of E‐cadherin expression and recurrence of hepatocellular carcinoma, Hepatogastroenterology, 46, 1923

10.1046/j.1440-1746.2003.03021.x

10.1016/S0092-8674(01)00365-8

Gwak GY, 2006, Anti‐apoptotic N‐cadherin signaling and its prognostic implication in human hepatocellular carcinomas, Oncol Rep, 15, 1117

Thông tin
Thông tin xuất bản

Pathology International

Tập 58 Số 10

635-642

Thông tin tác giả